Innocent Drinks founder Richard Reed and Businessman Jim Mellon amongst investors into groundbreaking psychedelic medicine company

Funding | Healthcare | Latest News | North West | South East | South West
Beckley Psytech cofounders Cosmo Feilding-Mellen and Lady Amanda Feilding. Credit: Luke MacGregor/Bloomberg

Beckley Psytech, the psychedelic medicine company, has raised £3m of Series A funding to develop a pipeline of psychedelic drugs into licensed pharmaceutical medicines for treating psychiatric and neurological diseases.

Investors in the round include prominent British businessmen Jim Mellon and Richard Reed, co-founder of Innocent Drinks.

The prevalence of mental health and central nervous system (CNS) disorders is growing year on year, with roughly 1 in 4 people₁ around the world affected by these conditions in their lifetimes, and with mental health set to become the biggest disease burden globally, potentially exacerbated by the current pandemic.

Existing treatments are often sub-optimal and may cause treatment limiting side-effects 2, however currently controlled “psychedelic” drugs such as psilocybin and MDMA have shown early promise in the treatment of debilitating mental and neurological disorders.

Beckley Psytech will use the Series A funding to advance its lead programme exploring the use of synthetic 5-MeO-DMT, a unique psychedelic agent with a short duration of action, in the treatment of neuropsychiatric diseases.

The funding will help with scaling up resources to develop novel pharmaceutical formulations and delivery methods for synthetic 5-MeO-DMT, as well as to progress preclinical and clinical trials.

Cosmo Feilding Mellen, co-founder and CEO, Beckley Psytech, says: “Our diverse and experienced leadership team is perfectly positioned to deliver on our mission of making effective and safe psychedelic medicines available to patients in need and integrating these treatments into mainstream medical practice.

“This investment comes at an exciting time as we look to build on our progress into an area with transformational potential for society. The capital will enable us to put more resources into exploring 5-MeO-DMT and creating a viable pathway for it to enter the market, as well as the exploration of other agents.”

Dr Steve Wooding, Chief Scientific Officer, Beckley Psytech, says: “There is a significant market opportunity for psychedelic medicines and we are developing a pipeline of assets which we hope will deliver transformative care to patients.

“Beckley Psytech will capitalise on its unique medical, scientific and commercial connections to develop under-researched psychedelic agents into fully licensed medicines that could significantly improve quality of life for patients suffering from intractable, chronic mental and neurological conditions.”

Did you enjoy reading this content?  To get more great content like this subscribe to our magazine

Reader's Comments

Comments related to the current article

Leave a comment

Your email address will not be published. Required fields are marked *